Human Interleukin-13 (Highly Pure)

<strong>Human Interleukin-13 (Highly Pure)</strong>_x000D_ <strong>Catalog number:</strong> B2010288_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 ug_x000D_ <strong>pH:</strong> 7.4 upon reconstitution_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure Human Interleukin-13 (Highly Pure) expressed in CHO cells. This protein acts as a cytokine which affects the morphology, growth, and surface antigen expression and phenotype of monocytes and elicits B cell proliferation._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> rHuIL-13; NC30, IL-13_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Gomes IA, de Carvalho FO, de Menezes AF, Almeida FM, Shanmugam S, de Souza_x000D_ Siqueira Quintans J, Quintans-Júnior LJ, de Moura TR, Oliveira PD, de Souza_x000D_ Araújo AA. The role of interleukins in vitiligo: a systematic review. J Eur Acad_x000D_ Dermatol Venereol. 2018 Dec;32(12):2097-2111._x000D_ _x000D_ 2: Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for_x000D_ new anti-cancer drug development. Mol Cancer. 2017 Sep 19;16(1):153._x000D_ _x000D_ 3: Elmslie RE, Dow SW, Ogilvie GK. Interleukins: biological properties and_x000D_ therapeutic potential. J Vet Intern Med. 1991 Sep-Oct;5(5):283-93._x000D_ _x000D_ 4: Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1_x000D_ cytokine family--Balance between agonists and antagonists in inflammatory_x000D_ diseases. Cytokine. 2015 Nov;76(1):25-37._x000D_ _x000D_ 5: Chen J, Ma A. Associations of polymorphisms in interleukins with_x000D_ tuberculosis: Evidence from a meta-analysis. Immunol Lett. 2020 Jan;217:1-6._x000D_ _x000D_ 6: Rozycki HJ, Zhao W. Interleukins for the paediatric pulmonologist. Paediatr_x000D_ Respir Rev. 2014 Mar;15(1):56-68._x000D_ _x000D_ 7: Quesniaux VF. Interleukins 9, 10, 11 and 12 and kit ligand: a brief overview._x000D_ Res Immunol. 1992 May;143(4):385-400._x000D_ _x000D_ 8: Herrod HG. Interleukins in immunologic and allergic diseases. Ann Allergy._x000D_ 1989 Oct;63(4):269-72._x000D_ _x000D_ 9: Akiyama M. Regarding "Upregulated interleukins (IL-6, IL-10, and IL-13) in_x000D_ immunoglobulin G4-related aortic aneurysm patients". J Vasc Surg. 2017_x000D_ Dec;66(6):1919._x000D_ _x000D_ 10: Candel-Martí ME, Flichy-Fernández AJ, Alegre-Domingo T, Ata-Ali J,_x000D_ Peñarrocha-Diago MA. Interleukins IL-6, IL-8, IL-10, IL-12 and periimplant_x000D_ disease. An update. Med Oral Patol Oral Cir Bucal. 2011 Jul 1;16(4):e518-21._x000D_ _x000D_ 11: Behzadi P, Behzadi E, Ranjbar R. IL-12 Family Cytokines: General_x000D_ Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways._x000D_ Acta Microbiol Immunol Hung. 2016 Mar;63(1):1-25._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/7806947/">12: Holcombe RF. Clinical applications of the interleukins: present and future._x000D_ J La State Med Soc. 1994 Nov;146(11):479-83. </a>_x000D_ _x000D_ <strong>Products Related to Human Interleukin-13 (Highlly Pure) </strong> <a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>